Fine-needle aspiration of primary osseous lesions: A cost effectiveness study.
Fine-needle aspiration (FNA) is not widely used in the work-up of osseous lesions because of concerns regarding its high incidence of nondiagnostic specimens. Although several studies have shown that FNA is less expensive than surgical biopsy, the authors are aware of only one prior study evaluating the cost effectiveness of FNA, which includes the cost of incisional or core needle biopsies necessary to establish a diagnosis when the initial FNA was noncontributory. A computerized search of the pathology records of three medical centers was performed to obtain all FNAs of primary osseous lesions. For each FNA case, all subsequent core needle, incisional or excisional biopsies were recorded as was the result of the definitive operative procedure. The cost of obtaining the definitive diagnosis was calculated for each case including the cost of FNA, imaging guidance utilized, and cost of subsequent surgical biopsy when necessary. The cost of an alternate approach using only surgical biopsy was calculated. The average per patient costs of these two protocols were compared.A total of 165 primary bone tumors underwent FNA. One hundred six of these yielded a definitive cytologic diagnosis. In 59 cases, FNA yielded a result insufficient for definitive therapy necessitating surgical biopsy. FNA investigation of the 165 bone lesions cost 575,932 (average of 3,490 per patient). Surgical biopsy alone would have cost 5,760 per patient. FNA resulted in a cost savings of 2,215 per patient.
Layfield
Lester J
LJ
Department of Pathology, University of Utah Medical Center, Salt Lake City, UT 84112, USA. layfiel@aruplab.com
Dodd
Leslie G
LG
Hirschowitz
Sharon
S
Crabtree
Susie Newman
SN
D044963:Biopsy, Fine-Needle / Q000191:economics*; D001859:Bone Neoplasms / Q000175:diagnosis / Q000191:economics* / Q000473:pathology* / Q000601:surgery; D001842:Bone and Bones / Q000473:pathology*; D003362:Cost-Benefit Analysis; D003663:Decision Trees; D006801:Humans